Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02340117 · ClinicalTrials.gov registry record · Phase 2

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

A Phase 2 study of Metastatic Pancreatic Cancer, sponsored by SynerGene Therapeutics.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT02340117 is a Phase 2 study of Metastatic Pancreatic Cancer that is active but no longer recruiting, run by SynerGene Therapeutics. The registered enrollment target is 28 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02340117, a Phase 2 study of Metastatic Pancreatic Cancer, is active but no longer recruiting, sponsored by SynerGene Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer. The objective of the study is to evaluate the safety, tolerability, toxicity and efficacy (specifically Progression Free Survival at 5.5 month (PFS5.5mos)) of this combination therapy.

Conditions Studied

Metastatic Pancreatic Cancer

Interventions

  • DRUG Gemcitabine
  • DRUG nab-paclitaxel
  • GENETIC SGT-53

Study Locations (1)

Texas

  • Mary Crowley Cancer Research Center - Dallas

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2015-01
Est. Completion 2026-12
Phase Phase 2

Sponsor

SynerGene Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02340117

The ClinicalTrials.gov registry entry for NCT02340117 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (74% lower). The listed sponsor is SynerGene Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.

NCT02340117 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02340117 about?

NCT02340117 is a clinical study titled "Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer". This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer. The objective of the study is to evaluate the safety, tolerability, toxicity and efficacy (specifically Progressio...

What is the current status of trial NCT02340117?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2015-01. Estimated completion is 2026-12.

What conditions does trial NCT02340117 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.

What interventions are being tested in trial NCT02340117?

The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), SGT-53 (GENETIC).

Who is sponsoring clinical trial NCT02340117?

This trial is sponsored by SynerGene Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02340117 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Pancreatic Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.